Navigation Links
Commercial Launch of Lexiscan(TM) (Regadenoson) Injection Triggers $10 Million Milestone Payment from TPG-Axon Capital to CV Therapeutics
Date:6/24/2008

xecutive officer. "Our partners at Astellas are the market leaders in the MPI market and are very well positioned for commercial success."

CV Therapeutics owns the rights for regadenoson outside of North America and currently expects to submit a marketing authorization application for the product to the European Medicines Agency by the end of 2008.

Astellas Pharma US, Inc. / CV Therapeutics Inc. Collaboration

Under a license and collaboration agreement providing Astellas with exclusive North American rights to Lexiscan(TM) (regadenoson) injection, CV Therapeutics completed the development program and Astellas is responsible for all commercial activities for the product in North America. Under the arrangement, Astellas paid CV Therapeutics a $7 million milestone upon submission of the new drug application to the FDA, and a $12 million milestone in April 2008. Astellas also reimburses CV Therapeutics for 75 percent of development costs. CV Therapeutics will receive a royalty on product sales of Lexiscan(TM) (regadenoson) injection, and may receive a royalty on another Astellas product.

About Lexiscan(TM) (regadenoson) injection

Lexiscan(TM) is an A2A adenosine receptor agonist approved for use as a pharmacologic stress agent in radionuclide MPI studies in patients unable to undergo adequate exercise stress. Lexiscan(TM) was designed to produce coronary vasodilation and increase coronary blood flow by activation of the A2A adenosine receptor. Lexiscan(TM) is administered as a rapid bolus (approximately 10 seconds) with no dose adjustment required for body weight. Lexiscan(TM) should not be administered to patients with second- or third-degree AV block or sinus node dysfunction who do not have a functioning artificial pacemaker. Adenosine receptor agonists, including Lexiscan(TM), induce arterial vasodilation and hypotension. The risk of serious hypotension may be higher in patients with cardiac or cerebrovascular insufficiency. Comple
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. SAFC Expands European Commercial Manufacturing and Storage Capacities With $10 Million Investment
2. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
3. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
4. ADVENTRX Appoints Vice President of Commercialization
5. Pharmaceutical Product Launch: Commercially Focused R&D Increases Drugs Market Potential
6. Accera, Inc. Names William T. Poncy Vice President of Commercial Development
7. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
8. Genencor Launches First Ever Commercial Enzyme Product for Cellulosic Ethanol
9. Affymax(R) and Takeda Recognized for Innovative Global Agreement to Develop and Commercialize Hematide(TM) for Anemia
10. Neurocrine Biosciences and Dainippon Sumitomo Pharma (DSP) Announce Agreement to Develop and Commercialize Indiplon in Japan
11. Product Development Timelines and Commercialization Strategy Are Focus of New Group at Premier Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 DTS Language Services, Inc . ... Portal for Life Science organizations who need document translations. ... matter of their documents in advance with a selection of ... of translations, often a critical factor in clinical and scientific ...
(Date:1/15/2014)... Jan. 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") ... with R-Pharm, a leading Russian pharmaceutical company, to develop ... Russian Federation , Turkey ... (CIS). Nemonoxacin is a novel antibiotic for the treatment of ...
(Date:1/14/2014)... provider of strategic communications services to corporations and organizations preparing for ... United States and Europe , today ... to the firm,s Washington, D.C. office. ... years of service as Associate Commissioner for the Office of External ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014  Organovo announced ... from the National Institutes of Health (NIH) to help ... effective treatments to patients on a faster timeline. Organovo ... Sciences (NCATS) and the National Eye Institute (NEI) to ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3
... nation's dysfunctional healthcare system may undermine any progress in patient ... according to a featured speaker at this week's Digital ... Jeff Grossman, president and CEO of the University of Wisconsin ... IT in healthcare delivery. As he outlined the remaining barriers ...
... Wis. They can cost as much as buildings ... possible if the right people are involved and excited, said ... WTN Media. , ,"User ownership is absolutely essential," said Peter ... don't know the application, if they don't feel they're being ...
... research projects on his campus will get ahead by ... you. , ,"Let's get real," Santiago told listeners at ... education in Wisconsin. "(UW-Milwaukee research programs) are not competing ... their evolution." , ,Likewise, don't suggest to Santiago that ...
Cached Biology Technology:U.S. health system could undermine EHR progress 2U.S. health system could undermine EHR progress 3Healthcare leaders tell how they rally stakeholders around IT 2Why Milwaukee needs its own thriving research base 2Why Milwaukee needs its own thriving research base 3
(Date:7/9/2014)... the bladders of healthy women differ from bacteria ... according to researchers from Loyola University Chicago Stritch ... July 9, 2014, in the American Society for ... bacterial communities may play a role in female ... a common, yet poorly understood, condition with symptoms ...
(Date:7/9/2014)... Indiana state parks have helped restore the health of ... populations of white-tailed deer, a Purdue study shows. , ... of forest ecology, found that a 17-year-long Indiana Department ... parks has successfully spurred the regrowth of native tree ... , Jenkins said that while hunting may be ...
(Date:7/9/2014)... RIVERSIDE, Calif. Sexual selection refers to species, selection ... This special type of natural selection enhances opportunities to ... example. , Biologists at the University of California, Riverside ... the formation of a placenta are linked. Describing ... fish in the family Poeciliidae, the researchers found that ...
Breaking Biology News(10 mins):Hunting gives deer-damaged forests in state parks a shot at recovery 2Biologists link sexual selection and placenta formation 2Biologists link sexual selection and placenta formation 3Biologists link sexual selection and placenta formation 4
... (FDA) today approved Symlin, an injectable medicine to control blood ... Symlin is to be used in addition to insulin therapy ... sugars on intensive insulin therapy alone. , Symlin will be ... other than insulin. Patients with type 2 diabetes already have ...
... of Liverpool have discovered how fish have evolved over ... different water depths. , A research team led by ... of Biological Sciences, has revealed how modern fish, such ... floating at certain water levels using a gas-filled swimbladder. ...
... Genomed-Health 2005 workshop in Tunisia, supported by the ... sciences in improving health in countries bordering the ... the importance of Euro-Mediterranean partnerships in order to ... ?in particular following the mapping of the human ...
Cached Biology News:FDA Approves New Drug to Treat Type I and Type II Diabetes 2Scientists discover how fish evolved to float at different sea depths 2Measuring the impact of post-genomics on Mediterranean populations 2
... Clone/PAD: ZMD.330. Immunogen: Synthetic peptide derived ... rat and mouse protein kinase C zeta ... rat and mouse PKCzeta protein. Recognizes ... not cross-react with PKCiota/lambda. Reactivity: Mouse ...
Lipid-rich bovine serum albumin for cell culture. It is chromatographically purified and has an IgG content 1.0% (w/w)....
Request Info...
... Immunogen KLH-conjugated, ... acids 47-66 (PAEV-GPGAVGERTPRKKEPP) of human ... 1 (BHC110/LSD1). Quality Assurance ... Stability 2 ...
Biology Products: